Trial Profile
A phase 1B study of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Temsirolimus; Vinblastine
- Indications Anaplastic large cell lymphoma; Lymphoma; Neuroblastoma; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms CRISP
- 25 Aug 2022 This trial has been completed in Ireland, according to European Clinical Trials Database record.
- 08 Feb 2020 Planned number of patients changed from 82 to 94.
- 01 Aug 2019 This trial has been suspended in Netherlands, according to European Clinical Trials Database.